European Pharmacopoeia Commission Sets Priorities for Next Three Years
The commission approved future plans, appointed members, and adopted texts during its November 2016 session.
The European Pharmacopoeia Commission
announcedon Nov. 29, 2016 that, during its 156th session, the commission approved its working program activities until November 2019, which include actively involving observers and reviewing current processes and procedures. The commission also adopted 14 new texts and appointed chairpersons and members during the session.
New and revised texts that were adopted at the session will become effective January 1, 2018 and will be published in supplement 9.3 of the European Pharmacopoeia. The following texts were adopted:
- Three monographs elaborated under the P4 procedure (single-source products): Rupatadine fumarate (2888); Human coagulation factor IX (rDNA) powder for solution for injection (2994) and on Etanercept (2895)
- One monograph on Radiopharmaceutical preparations: sodium pertechnetate (99mTc) injection (accelerator-produced) (2891)
- Two new monographs on antibiotics: Tacrolimus (2244) and Tylosin phosphate for veterinary use (2802)
- Three new monographs on gases: carbon monoxide intermix (5% in nitrogen) (2904), Methane intermix (2%) in nitrogen (2905), and Acetylene intermix (1% in nitrogen) (2903)
- Monographs on: Nicardipine hydrochloride (2776); ammonium carbonate for homoeopathic preparations (2916) and Magnolia biondii flower bud (2742)
- Two new general chapters: In vivo assay substitution with in vitro methods for quality control of vaccines (5.2.14) and Chemical imaging (5.24.).
Also adopted were 52 revised monographs, including eight dosage form monographs and 11 revised general chapters. The commission also revised its implementation strategy for the International Council for Harmonization (ICH) Q3D guideline on elemental impurities during the session.
Source:
EDQM
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
